← Oncology Approval Tracker

FDA DECISION ·

Thyquidity

levothyroxine sodium · Stevens J

FDA approvalNew formulationWell-differentiated thyroid cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Oral solution approved for TSH suppression alongside surgery and radioiodine in thyrotropin-dependent well-differentiated thyroid cancer; the label also covered hypothyroidism.

LAMPGEN ANALYSIS

Why it matters

Added a liquid option for thyroid hormone suppression in the labeled cancer setting.

What research teams should watch

Verify solution concentration and dosing units and coordinate laboratory follow-up after changing formulations.

PRIMARY RECORDS

Sources